Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

R. Kodera, Kenichi Shikata, Hitomi Kataoka, T. Takatsuka, Satoshi Miyamoto, M. Sasaki, N. Kajitani, S. Nishishita, K. Sarai, D. Hirota, C. Sato, D. Ogawa, Hirofumi Makino

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Aims/hypothesis: Glucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1 receptor is produced in kidney tissue. However, the direct effect of GLP-1 on diabetic nephropathy remains unclear. Here we demonstrate that a GLP-1 receptor agonist, exendin-4, exerts renoprotective effects through its anti-inflammatory action via the GLP-1 receptor without lowering blood glucose. Methods: We administered exendin-4 at 10 μg/kg body weight daily for 8 weeks to a streptozotocin-induced rat model of type 1 diabetes and evaluated their urinary albumin excretion, metabolic data, histology and morphometry. We also examined the direct effects of exendin-4 on glomerular endothelial cells and macrophages in vitro. Results: Exendin-4 ameliorated albuminuria, glomerular hyperfiltration, glomerular hypertrophy and mesangial matrix expansion in the diabetic rats without changing blood pressure or body weight. Exendin-4 also prevented macrophage infiltration, and decreased protein levels of intercellular adhesion molecule-1 (ICAM-1) and type IV collagen, as well as decreasing oxidative stress and nuclear factor-κB activation in kidney tissue. In addition, we found that the GLP-1 receptor was produced on monocytes/macrophages and glomerular endothelial cells. We demonstrated that in vitro exendin-4 acted directly on the GLP-1 receptor, and attenuated release of pro-inflammatory cytokines from macrophages and ICAM-1 production on glomerular endothelial cells. Conclusions/interpretation: These results indicate that GLP-1 receptor agonists may prevent disease progression in the early stage of diabetic nephropathy through direct effects on the GLP-1 receptor in kidney tissue.

Original languageEnglish
Pages (from-to)965-978
Number of pages14
JournalDiabetologia
Volume54
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Type 1 Diabetes Mellitus
Blood Glucose
Anti-Inflammatory Agents
Kidney
Wounds and Injuries
Macrophages
Glucagon-Like Peptide 1
Endothelial Cells
Diabetic Nephropathies
Intercellular Adhesion Molecule-1
Body Weight
Albuminuria
Collagen Type IV
Insulin-Secreting Cells
Streptozocin
Glucagon-Like Peptide-1 Receptor
Hypertrophy
Disease Progression
exenatide
Monocytes

Keywords

  • Anti-inflammatory effect
  • Diabetic nephropathy
  • Exendin-4
  • Glomerular endothelial cells
  • GLP-1 receptor agonist
  • Intercellular adhesion molecule-1
  • Macrophage
  • Nuclear factor-κB
  • Type 1 diabetic rats

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. / Kodera, R.; Shikata, Kenichi; Kataoka, Hitomi; Takatsuka, T.; Miyamoto, Satoshi; Sasaki, M.; Kajitani, N.; Nishishita, S.; Sarai, K.; Hirota, D.; Sato, C.; Ogawa, D.; Makino, Hirofumi.

In: Diabetologia, Vol. 54, No. 4, 04.2011, p. 965-978.

Research output: Contribution to journalArticle

@article{30228ca42e9b4d86a889db21491e1742,
title = "Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes",
abstract = "Aims/hypothesis: Glucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1 receptor is produced in kidney tissue. However, the direct effect of GLP-1 on diabetic nephropathy remains unclear. Here we demonstrate that a GLP-1 receptor agonist, exendin-4, exerts renoprotective effects through its anti-inflammatory action via the GLP-1 receptor without lowering blood glucose. Methods: We administered exendin-4 at 10 μg/kg body weight daily for 8 weeks to a streptozotocin-induced rat model of type 1 diabetes and evaluated their urinary albumin excretion, metabolic data, histology and morphometry. We also examined the direct effects of exendin-4 on glomerular endothelial cells and macrophages in vitro. Results: Exendin-4 ameliorated albuminuria, glomerular hyperfiltration, glomerular hypertrophy and mesangial matrix expansion in the diabetic rats without changing blood pressure or body weight. Exendin-4 also prevented macrophage infiltration, and decreased protein levels of intercellular adhesion molecule-1 (ICAM-1) and type IV collagen, as well as decreasing oxidative stress and nuclear factor-κB activation in kidney tissue. In addition, we found that the GLP-1 receptor was produced on monocytes/macrophages and glomerular endothelial cells. We demonstrated that in vitro exendin-4 acted directly on the GLP-1 receptor, and attenuated release of pro-inflammatory cytokines from macrophages and ICAM-1 production on glomerular endothelial cells. Conclusions/interpretation: These results indicate that GLP-1 receptor agonists may prevent disease progression in the early stage of diabetic nephropathy through direct effects on the GLP-1 receptor in kidney tissue.",
keywords = "Anti-inflammatory effect, Diabetic nephropathy, Exendin-4, Glomerular endothelial cells, GLP-1 receptor agonist, Intercellular adhesion molecule-1, Macrophage, Nuclear factor-κB, Type 1 diabetic rats",
author = "R. Kodera and Kenichi Shikata and Hitomi Kataoka and T. Takatsuka and Satoshi Miyamoto and M. Sasaki and N. Kajitani and S. Nishishita and K. Sarai and D. Hirota and C. Sato and D. Ogawa and Hirofumi Makino",
year = "2011",
month = "4",
doi = "10.1007/s00125-010-2028-x",
language = "English",
volume = "54",
pages = "965--978",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

AU - Kodera, R.

AU - Shikata, Kenichi

AU - Kataoka, Hitomi

AU - Takatsuka, T.

AU - Miyamoto, Satoshi

AU - Sasaki, M.

AU - Kajitani, N.

AU - Nishishita, S.

AU - Sarai, K.

AU - Hirota, D.

AU - Sato, C.

AU - Ogawa, D.

AU - Makino, Hirofumi

PY - 2011/4

Y1 - 2011/4

N2 - Aims/hypothesis: Glucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1 receptor is produced in kidney tissue. However, the direct effect of GLP-1 on diabetic nephropathy remains unclear. Here we demonstrate that a GLP-1 receptor agonist, exendin-4, exerts renoprotective effects through its anti-inflammatory action via the GLP-1 receptor without lowering blood glucose. Methods: We administered exendin-4 at 10 μg/kg body weight daily for 8 weeks to a streptozotocin-induced rat model of type 1 diabetes and evaluated their urinary albumin excretion, metabolic data, histology and morphometry. We also examined the direct effects of exendin-4 on glomerular endothelial cells and macrophages in vitro. Results: Exendin-4 ameliorated albuminuria, glomerular hyperfiltration, glomerular hypertrophy and mesangial matrix expansion in the diabetic rats without changing blood pressure or body weight. Exendin-4 also prevented macrophage infiltration, and decreased protein levels of intercellular adhesion molecule-1 (ICAM-1) and type IV collagen, as well as decreasing oxidative stress and nuclear factor-κB activation in kidney tissue. In addition, we found that the GLP-1 receptor was produced on monocytes/macrophages and glomerular endothelial cells. We demonstrated that in vitro exendin-4 acted directly on the GLP-1 receptor, and attenuated release of pro-inflammatory cytokines from macrophages and ICAM-1 production on glomerular endothelial cells. Conclusions/interpretation: These results indicate that GLP-1 receptor agonists may prevent disease progression in the early stage of diabetic nephropathy through direct effects on the GLP-1 receptor in kidney tissue.

AB - Aims/hypothesis: Glucagon-like peptide-1 (GLP-1) has various extra-pancreatic actions, in addition to its enhancement of insulin secretion from pancreatic beta cells. The GLP-1 receptor is produced in kidney tissue. However, the direct effect of GLP-1 on diabetic nephropathy remains unclear. Here we demonstrate that a GLP-1 receptor agonist, exendin-4, exerts renoprotective effects through its anti-inflammatory action via the GLP-1 receptor without lowering blood glucose. Methods: We administered exendin-4 at 10 μg/kg body weight daily for 8 weeks to a streptozotocin-induced rat model of type 1 diabetes and evaluated their urinary albumin excretion, metabolic data, histology and morphometry. We also examined the direct effects of exendin-4 on glomerular endothelial cells and macrophages in vitro. Results: Exendin-4 ameliorated albuminuria, glomerular hyperfiltration, glomerular hypertrophy and mesangial matrix expansion in the diabetic rats without changing blood pressure or body weight. Exendin-4 also prevented macrophage infiltration, and decreased protein levels of intercellular adhesion molecule-1 (ICAM-1) and type IV collagen, as well as decreasing oxidative stress and nuclear factor-κB activation in kidney tissue. In addition, we found that the GLP-1 receptor was produced on monocytes/macrophages and glomerular endothelial cells. We demonstrated that in vitro exendin-4 acted directly on the GLP-1 receptor, and attenuated release of pro-inflammatory cytokines from macrophages and ICAM-1 production on glomerular endothelial cells. Conclusions/interpretation: These results indicate that GLP-1 receptor agonists may prevent disease progression in the early stage of diabetic nephropathy through direct effects on the GLP-1 receptor in kidney tissue.

KW - Anti-inflammatory effect

KW - Diabetic nephropathy

KW - Exendin-4

KW - Glomerular endothelial cells

KW - GLP-1 receptor agonist

KW - Intercellular adhesion molecule-1

KW - Macrophage

KW - Nuclear factor-κB

KW - Type 1 diabetic rats

UR - http://www.scopus.com/inward/record.url?scp=79953826349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953826349&partnerID=8YFLogxK

U2 - 10.1007/s00125-010-2028-x

DO - 10.1007/s00125-010-2028-x

M3 - Article

VL - 54

SP - 965

EP - 978

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 4

ER -